Takeaways: Health Canada’s approval of Dawnzera (donidalorsen) gives CELYSTRA a first‑in‑class, RNA‑targeted prophylaxis for hereditary angioedema (HAE) in patients ≥12 years, with Q4W/Q8W...
Takeaways: CELYSTRA is being set up as a dedicated Canadian “importer–operator” for advanced rare‑disease drugs, starting with RNA therapeutics. It’s led by senior ex‑big‑pha...
